These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs]. Hecht B Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402 [TBL] [Abstract][Full Text] [Related]
12. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis. Janiec K; Wajgt A; Kondera-Anasz Z Med Sci Monit; 2001; 7(1):93-8. PubMed ID: 11208501 [TBL] [Abstract][Full Text] [Related]
13. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced. Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090 [No Abstract] [Full Text] [Related]
14. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Beutler E; Sipe J; Romine J; McMillan R; Zyroff J; Koziol J Semin Hematol; 1996 Jan; 33(1 Suppl 1):45-52. PubMed ID: 8714617 [No Abstract] [Full Text] [Related]
15. [Cladribine]. Ogura M Gan To Kagaku Ryoho; 2003 Feb; 30(2):309-17. PubMed ID: 12610885 [TBL] [Abstract][Full Text] [Related]
16. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
17. Cladribine: from the bench to the bedside--focus on hairy cell leukemia. Greyz N; Saven A Expert Rev Anticancer Ther; 2004 Oct; 4(5):745-57. PubMed ID: 15485311 [TBL] [Abstract][Full Text] [Related]
18. 2-Chloro-2'-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy. Fabianowska-Majewska K; Wyczechowska D Acta Pol Pharm; 1996; 53(4):231-9. PubMed ID: 9415193 [TBL] [Abstract][Full Text] [Related]